WallStreetZenWallStreetZen

NASDAQ: SLN
Silence Therapeutics PLC Earnings & Revenue

SLN past revenue growth

How has SLN's revenue growth performed historically?
Company
21.37%
Industry
89.98%
Market
18.88%
SLN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SLN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SLN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SLN earnings and revenue history

Current Revenue
$33.9M
Current Earnings
-$44.8M
Current Profit Margin
-132.3%

SLN Return on Equity

Current Company
-80.7%
Current Industry
16.8%
Current Market
28.2%
SLN's Return on Equity (-80.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SLN announces earnings.

SLN Return on Assets

Current Company
-29.2%
Current Industry
3.2%
SLN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SLN Return on Capital Employed

Current Company
-21.11%
Current Industry
-42.4%

SLN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SLN$33.01M-$46.97M-$43.67M+31.00%N/A
LQDA$15.97M-$97.50M-$107.69M+55.06%N/A
COGT$0.00-$208.24M-$212.17M-100.00%N/A
ETNB$0.00-$157.09M-$165.03MN/AN/A
FDMT$20.45M-$98.63M-$104.56M+88.51%N/A

Silence Therapeutics Earnings & Revenue FAQ

What were SLN's earnings last quarter?

On Invalid Date, Silence Therapeutics (NASDAQ: SLN) reported Q1 2024 earnings per share (EPS) of N/A, up N/A year over year. Total Silence Therapeutics earnings for the quarter were -$2.41 million. In the same quarter last year, Silence Therapeutics's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Silence Therapeutics stock.

What was SLN's earnings growth in the past year?

As of Q3 2024, Silence Therapeutics's earnings has grown year over year. Silence Therapeutics's earnings in the past year totalled -$43.67 million.

What was SLN's revenue last quarter?

On Invalid Date, Silence Therapeutics (NASDAQ: SLN) reported Q1 2024 revenue of $15.91 million up 16.07% year over year. In the same quarter last year, Silence Therapeutics's revenue was $13.70 million.

What was SLN's revenue growth in the past year?

As of Q3 2024, Silence Therapeutics's revenue has grown 21.37% year over year. This is 68.61 percentage points lower than the US Biotechnology industry revenue growth rate of 89.98%. Silence Therapeutics's revenue in the past year totalled $33.01 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.